Leo Luznik, MD, Hematology, Baltimore, MD, Johns Hopkins Hospital

LeoLuznikMD

Hematology Baltimore, MD

Hematologic Oncology

Associate Professor of Oncology at Johns Hopkins University School of Medicine

Dr. Luznik is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Luznik's full profile

Already have an account?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFELLOWSHIP
  • Johns Hopkins University
    Johns Hopkins UniversityFELLOWSHIP
  • University of Arizona
    University of ArizonaRESIDENCY
  • University of California at San Diego
    University of California at San DiegoPOST_DOCTORAL_FELLOWSHIP
  • University of Zagreb Faculty of Medicine
    University of Zagreb Faculty of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1997 - 2022

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
    Leo Luznik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...
    Leo Luznik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or M...
    Leo Luznik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Spoiled for Choice: Donor Selection for Allogeneic Stem Cell Transplantation 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • Drug Regimen Enough to Control Immune Disease After Some Bone Marrow Transplants
    Drug Regimen Enough to Control Immune Disease After Some Bone Marrow TransplantsOctober 08, 2014
  • How Common Chemo Drug Thwarts Graft Rejection in Bone Marrow Transplants
    How Common Chemo Drug Thwarts Graft Rejection in Bone Marrow TransplantsNovember 13, 2013

Hospital Affiliations